Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low

被引：9

作者：

Fan, Pinchao ^{[1
]}

Xu, Kun ^{[2
,3
,4
]}

机构：

[1] Nanjing Med Univ, Clin Med Coll 1, Nanjing 211166, Peoples R China

[2] Nanjing Med Univ, Jiangsu Canc Hosp, Dept Oncol, 42 Baiziting, Nanjing 210009, Peoples R China

[3] Nanjing Med Univ, Jiangsu Inst Canc Res, 42 Baiziting, Nanjing 210009, Peoples R China

[4] Nanjing Med Univ, Affiliated Canc Hosp, 42 Baiziting, Nanjing 210009, Peoples R China

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2023年 / 1878卷 / 01期

关键词：

Antibody-drug conjugate; Breast cancer; HER2-overexpression; HER2-low; TRASTUZUMAB EMTANSINE T-DM1; SACITUZUMAB GOVITECAN; SINGLE-ARM; CHEMOTHERAPY; EXPRESSION; METASTASES; THERAPY; DISEASE; COHORT; TUMORS;

D O I：

10.1016/j.bbcan.2022.188849

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The recent decade has witnessed a vigorous prosper of antibody-drug conjugates (ADCs) in solid tumors including breast cancer. Integrating the specificity of monoclonal antibodies and potency of cytotoxic drugs, ADCs are capable of delivering cytotoxic agents directly to tumor cells and surrounding accomplices with het-erogeneous antigen expression by exerting the distinctive bystander effect. Up till now, three ADCs (T-DM1, T-DXd and SG) have attained the official approval and stepped into clinical practices in breast cancer, with numerous promising products in the pipeline. As an unprecedented breast cancer subgroup identified following solidified drug benefit, the cognitive and therapeutic paradigm of HER2-low population which was previously thought lacking definite targets and efficacious regimens has been thoroughly rewritten by ADCs, and several encouraging achievements are expected in ongoing trials. Herein, we discuss the contrived knowledge, latest advancements and future perspectives of ADCs in HER2-overexpressing and HER2-low breast cancer.

引用

页数：12

共 99 条

[1] Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer [J].

Almstedt, Katrin ;

Heimes, Anne-Sophie ;

Kappenberg, Franziska ;

Battista, Marco J. ;

Lehr, Hans-Anton ;

Krajnak, Slavomir ;

Lebrecht, Antje ;

Gehrmann, Mathias ;

Stewen, Kathrin ;

Brenner, Walburgis ;

Weikel, Wolfgang ;

Rahnenfuehrer, Joerg ;

Hengstler, Jan G. ;

Hasenburg, Annette ;

Schmidt, Marcus .

EUROPEAN JOURNAL OF CANCER, 2022, 173 :10-19

[2] FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer [J].

Amiri-Kordestani, Laleh ;

Blumenthal, Gideon M. ;

Xu, Qiang Casey ;

Zhang, Lijun ;

Tang, Shenghui W. ;

Ha, Linan ;

Weinberg, Wendy C. ;

Chi, Bo ;

Candau-Chacon, Reyes ;

Hughes, Patricia ;

Russell, Anne M. ;

Miksinski, Sarah Pope ;

Chen, Xiao Hong ;

McGuinn, W. David ;

Palmby, Todd ;

Schrieber, Sarah J. ;

Liu, Qi ;

Wang, Jian ;

Song, Pengfei ;

Mehrotra, Nitin ;

Skarupa, Lisa ;

Clouse, Kathleen ;

Al-Hakim, Ali ;

Sridhara, Rajeshwari ;

Ibrahim, Amna ;

Justice, Robert ;

Pazdur, Richard ;

Cortazar, Patricia .

CLINICAL CANCER RESEARCH, 2014, 20 (17) :4436-4441

[3] Irinotecan: 25 years of cancer treatment [J].

Bailly, Christian .

PHARMACOLOGICAL RESEARCH, 2019, 148

[4] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study [J].

Banerji, Udai ;

van Herpen, Carla M. L. ;

Saura, Cristina ;

Thistiethwaite, Fiona ;

Lord, Simon ;

Moreno, Victor ;

Macpherson, Iain R. ;

Boni, Valentina ;

Rolfo, Christian ;

de Vries, Elisabeth G. E. ;

Rottey, Sylvie ;

Geenen, Jilt ;

Eskens, Ferry ;

Gil-Martin, Marta ;

Mommers, Ellen C. ;

Koper, Norbert P. ;

Aftimos, Philippe .

LANCET ONCOLOGY, 2019, 20 (08) :1124-1135

[5] Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer [J].

Bardia, A. ;

Tolaney, S. M. ;

Punie, K. ;

Loirat, D. ;

Oliveira, M. ;

Kalinsky, K. ;

Zelnak, A. ;

Aftimos, P. ;

Dalenc, F. ;

Sardesai, S. ;

Hamilton, E. ;

Sharma, P. ;

Recalde, S. ;

Gil, E. C. ;

Traina, T. ;

O'Shaughnessy, J. ;

Cortes, J. ;

Tsai, M. ;

Vahdat, L. ;

Dieras, V ;

Carey, L. A. ;

Rugo, H. S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. ;

Itri, L. M. ;

Hurvitz, S. A. .

ANNALS OF ONCOLOGY, 2021, 32 (09) :1148-1156

[6] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[7] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Mayer, I. A. ;

Vahdat, L. T. ;

Tolaney, S. M. ;

Isakoff, S. J. ;

Diamond, J. R. ;

O'Shaughnessy, J. ;

Moroose, R. L. ;

Santin, A. D. ;

Abramson, V. G. ;

Shah, N. C. ;

Rugo, H. S. ;

Goldenberg, D. M. ;

Sweidan, A. M. ;

Iannone, R. ;

Washkowitz, S. ;

Sharkey, R. M. ;

Wegener, W. A. ;

Kalinsky, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) :741-751

[8] Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer [J].

Bardia, Aditya ;

Mayer, Ingrid A. ;

Diamond, Jennifer R. ;

Moroose, Rebecca L. ;

Isakoff, Steven J. ;

Starodub, Alexander N. ;

Shah, Nikita C. ;

O'Shaughnessy, Joyce ;

Kalinsky, Kevin ;

Guarino, Michael ;

Abramson, Vandana ;

Juric, Dejan ;

Tolaney, Sara M. ;

Berlin, Jordan ;

Messersmith, Wells A. ;

Ocean, Allyson J. ;

Wegener, William A. ;

Maliakal, Pius ;

Sharkey, Robert M. ;

Govindan, Serengulam V. ;

Goldenberg, David M. ;

Vahdat, Linda T. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2141-+

[9] Cleavable linkers in antibody-drug conjugates [J].

Bargh, Jonathan D. ;

Isidro-Llobet, Albert ;

Parker, Jeremy S. ;

Spring, David R. .

CHEMICAL SOCIETY REVIEWS, 2019, 48 (16) :4361-4374

[10] Trastuzumab emtansine: mechanisms of action and drug resistance [J].

Barok, Mark ;

Joensuu, Heikki ;

Isola, Jorma .

BREAST CANCER RESEARCH, 2014, 16 (02)

← 1 2 3 4 5 6 7 8 9 10 →